β-d-Glucan kinetics for the assessment of treatment response in Pneumocystis jirovecii pneumonia.

Serum (1→3)-β-D-Glucan (BG) is a biomarker for Pneumocystis jirovecii pneumonia (PJP). However, information concerning its usefulness for monitoring the clinical course is lacking. We conducted a retrospective study to investigate whether consecutive BG-measurements can be used to assess treatment response in PJP. Analysis of sera from 18 patients during PJP therapy shows that decreasing BG-levels strongly correlate with a favourable clinical course. In contrast, increasing BG-levels were associated with treatment failure or fatal outcome is only 44% of patients. As a consequence, BG-kinetics might be used to confirm treatment success but seem to be of limited value for the identification of treatment failure.

[1]  J. Held,et al.  Serum (1 → 3)-β-D-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  I. Kocmanova,et al.  Difficulties in using 1,3-{beta}-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies--high frequency of false-positive results and their analysis. , 2010, Journal of medical microbiology.

[3]  J. Perfect,et al.  The (1,3)β-d-Glucan Test as an Aid to Early Diagnosis of Invasive Fungal Infections following Lung Transplantation , 2010, Journal of Clinical Microbiology.

[4]  T. Benfield,et al.  Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. , 2009, The Journal of antimicrobial chemotherapy.

[5]  H. Yazaki,et al.  Serum (1-->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Verhaegen,et al.  Hematological Malignancy Immunodeficiency Virus Infection or Pneumonia in Patients with Human Pneumocystis jirovecii Diagnosis ofd-Glucan as a Tool for β Serum ( 1-3 ) , 2009 .

[7]  C. Beard,et al.  Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations and Human Immunodeficiency Virus‐Associated Pneumocystis Pneumonia , 2006, The Journal of eukaryotic microbiology.

[8]  M. Usami,et al.  Positive (1→3)‐β‐d‐glucan in blood components and release of (1→3)‐β‐d‐glucan from depth‐type membrane filters for blood processing , 2002 .

[9]  Kazuhiko Yamamoto,et al.  Influence of various hemodialysis membranes on the plasma (1→3)-β-D-glucan level , 2001 .

[10]  A. Serr,et al.  Detection of Pneumocystis carinii DNA in Patients with Chronic Lung Diseases , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[11]  T. Shimazu,et al.  False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products , 1989, Journal of clinical microbiology.